Quince Therapeutics (QNCX) Registration filing summary

Use of proceeds and capital allocation

• Registration covers resale of up to 15,470,099 shares of common stock, including shares from recent merger and PIPE financing.

• Shares include those issued or issuable upon conversion of Series C Non-Voting Convertible Preferred Stock and exercise of warrants.

Risk factors and disclosures

• Indemnification agreements in place for directors and officers, providing maximum protection under Delaware law.

• Limitation of liability for directors for monetary damages, except in cases of breach of loyalty, bad faith, or unlawful acts.

• SEC notes indemnification for Securities Act liabilities may be unenforceable as against public policy.

Management team and governance

• CEO and Chief Medical Officer is Dirk Thye, M.D.; Chief Business Officer and COO is Brendan Hannah.

• Board includes David A. Lamond, June Bray, Brigette Roberts, M.D., and Christopher J. Senner.